• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Lamellar Biomedical launches dry-eye trial

May 31, 2017 By Sarah Faulkner

Lamellar BiomedicalLamellar Biomedical said today that the 1st patients were enrolled in its trial evaluating Lamelleye for the treatment of moderate to severe dry-eye disease.

Lamelleye uses the Scotland-based company’s Lamellasome technology to mimic the actions of serous lamellar bodies and regulate interfaces between tissues and external environments.

The trial is slated to compare Lamelleye to Optive Plus, a leading over-the-counter eye drop in patients with dry-eye disease.

The 30-patient study is expected to yield results in the 2nd half of this year. It is designed to evaluate the relative effectiveness of Lamelleye compared to Optive Plus based on outcomes such as invasive tear breakup time, symptom scores and rate of tear film evaporation.

“We believe that Lamelleye has the potential to be an important advance in the treatment of DED given the unique lubricating properties of our Lamellasome technology,” CEO Alec McLean said in prepared remarks. “We anticipate that this new study will provide conclusive evidence of the clinical benefits that Lamelleye can deliver and demonstrate its superiority over an existing product for the relief of dry eye disease. We are looking forward to announcing the results of the study later this year, as they will be used to support the commercialization of this exciting new treatment in Europe in 2018, through a partner.”

The company’s Lamelleye won CE Mark clearance in the European Union in 2015.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Wall Street Beat Tagged With: lamellarbiomedical

IN CASE YOU MISSED IT

  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen
  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS